Predicting Locally Advanced Rectal Cancer Response to NCT and NCRT With MRI

Predicting Locally Advanced Rectal Cancer Response to NCT and NCRT With MRI, and Comparison of MR Imaging Evaluation Between NCT and NCRT

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04392609

Enrollment

180

Registered

2020-05-19

Start date

2020-01-15

Completion date

2020-07-15

Last updated

2020-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MRI, Rectal Cancer

Brief summary

This trial was designed to to study whether there is a difference in MRI image evaluation between NCRT and NCT, and try to build a model to predict the efficacy of neoadjuvant therapy by combining multiple imaging indexes.

Detailed description

This study was designed as a retrospective case-control study. All 116 patients with locally advanced rectal cancer who started neoadjuvant chemoradiotherapy and underwent radical surgery in West of China Hospital and completed the required MR examination before and after neoadjuvant treatment were included from March 2016 to December 2019. MRI imaging indicators of patients before and after neoadjuvant therapy, including tumor location, longitudinal diameter, circumferential Angle, DWI signal, mrTRG and texture feature data, were retrospectively collected to analyze the changes before and after treatment, and compared with patients receiving NCT in PART1. At the same time, indicators with statistical differences will be included in the construction of models predicting different pathological outcomes after NCT and NCRT, and the efficacy of the models was evaluated through c-index values and ROC analysis of bootstrap resampling 500 times.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. pathological diagnosis of rectal cancer; 2. received neoadjuvant chemoradiotherapy before surgery; 3. before neoadjuvant therapy and before surgery, the patients received thin and high resolution MRI examination of the rectum. 4. before neoadjuvant therapy, colonoscopy, rectal contrast-enhanced ultrasound or MRI showed that the lower margin of the tumor was within 12cm from the anal margin; 5. pre-neoadjuvant clinical stage II/III (AJCC 7th edition);

Exclusion criteria

1. simultaneous distant metastatic tumor should be considered at the first diagnosis; 2. patients with distant metastasis were not considered at the initial diagnosis; 3. with other malignant tumors; 4. before neoadjuvant therapy, patients had received other relevant treatments; 5. to undergo palliative surgery or emergency surgery in the course of neoadjuvant therapy;

Design outcomes

Primary

Measure	Time frame	Description
pTRG	within 2 week after surgery	pathological tumour regression grading

Countries

China

Contacts

Primary ContactZiqiang Wang, MD

wangtrial@163.com18980602028

Outcome results